Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients

Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients

Information Release

Wednesday, April 12, 2023

The Nationwide Most cancers Institute, part of the National Institutes of Well being (NIH), has helped start a stage 3 randomized scientific trial (NCT05633602) of a two-drug mixture to treat people with state-of-the-art non-compact cell lung cancer (NSCLC). Known as the Pragmatica-Lung Analyze (or S2302), this is one particular of the first NCI-supported medical trials to use a demo structure that eliminates many of the boundaries that stop people today from signing up for scientific trials. This “pragmatic” tactic aims to increase accessibility to clinical trials.

The review is part of a broader effort and hard work by NIH and the U.S. Food and Drug Administration (Fda) to modernize clinical trials. Pragmatic scientific trials have less and simpler eligibility requirements than typical trials, while continue to guaranteeing the safety of people. The hope is that this variety of simplified demo can be significantly less burdensome to patients and investigators, accrue analyze members quicker, be extra consultant of the authentic-planet affected individual populace, and serve as a model for upcoming cancer clinical trials.

“This examine is made to eradicate prospective limitations to enrollment and offers a model for raising range and enrollment in scientific trials,” stated Monica M. Bertagnolli, M.D., director of NCI. “Pragmatica-Lung, with its essential general public and non-public partnerships, reflects the modern techniques NCI is taking to reach the Cancer Moonshot℠ targets, like minimizing the cancer loss of life fee by 50{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} within the next 25 years.”

The trial will appraise irrespective of whether a combination of two Fda-accepted drugs, ramucirumab (Cyramza, made by Eli Lilly and Corporation) and pembrolizumab (Keytruda, made by Merck), increases all round survival (how lengthy people today reside) above typical remedy in persons with innovative NSCLC whose disease has progressed soon after past therapy with immunotherapy and chemotherapy.

“These trials will make it simpler for doctors who do not do the job in massive tutorial healthcare centers to enroll their individuals, resulting in participation by extra assorted populations,” stated James H. Doroshow, M.D., director of NCI’s Division of Most cancers Remedy and Prognosis. “Making trials extra available, when upholding arduous scientific and basic safety expectations, suggests that additional health and fitness treatment practitioners and clients will have an possibility to participate.”

The demo will enroll up to 700 contributors from all-around the United States. Older people ages 18 and older with phase 4 or recurrent NSCLC who have been earlier addressed with immune checkpoint inhibitors (a kind of immunotherapy) and chemotherapy will be randomly assigned to receive possibly ramucirumab plus pembrolizumab or standard therapy. The research will glimpse primarily at how long clients in the two groups reside and is predicted to comprehensive enrollment by the close of 2025.

Pragmatica-Lung seeks to confirm the encouraging results of a randomized stage 2 scientific demo (S1800A) executed as element of the Lung Most cancers Learn Protocol (Lung-MAP), the 1st lung most cancers precision medication trial supported by NCI. That trial concerned 136 sufferers with superior NSCLC who experienced been earlier handled with chemotherapy and immunotherapy, and it uncovered proof that the blend of ramucirumab furthermore pembrolizumab extended survival when compared with typical procedure. Ramucirumab is a focused drug that performs by blocking new blood vessels from increasing, and pembrolizumab is an immunotherapy that allows the body’s immune technique assault the cancer.

The pragmatic method is most ideal for trials in which the medicines remaining examined have previously been authorised and their facet outcomes are very well comprehended, Dr. Doroshow reported.

NCI collaborators for the Pragmatica-Lung Research consist of the SWOG Cancer Exploration Network, which intended and is main the trial in collaboration with the Alliance for Scientific Trials in Oncology.

The analyze will be carried out with the participation of SWOG, Alliance, and two other U.S. NCI Countrywide Scientific Trials Community (NCTN) groups that aim on cancer in grownups, ECOG-ACRIN Most cancers Research Group and NRG Oncology.With each other, these four NCTN teams depict more than 1,600 most cancers therapy institutions in the United States, and physicians from any of these internet sites can enroll individuals on the demo.

About the Nationwide Most cancers Institute (NCI): NCI leads the National Cancer Method and NIH’s attempts to radically cut down the prevalence of cancer and enhance the life of cancer sufferers and their families, by investigation into prevention and most cancers biology, the development of new interventions, and the coaching and mentoring of new scientists. For extra facts about cancer, be sure to pay a visit to the NCI web site at www.most cancers.gov or connect with NCI’s call heart, the Most cancers Information Service, at 1-800-4-Most cancers (1-800-422-6237).

About the Countrywide Institutes of Wellness (NIH):&#13
NIH, the nation’s medical investigate company, includes 27 Institutes and Facilities and is a component of the U.S. Section of Health and fitness and Human Solutions. NIH is the most important federal agency conducting and supporting fundamental, medical, and translational health-related study, and is investigating the will cause, solutions, and cures for both frequent and exceptional illnesses. For extra information about NIH and its plans, stop by www.nih.gov.

NIH…Turning Discovery Into Health®

###

FDA outlines plan for digital health technologies for clinical trials

FDA outlines plan for digital health technologies for clinical trials
The US Foods and Drug Administration (Food and drug administration) programs to maintain at least one particular community assembly and launch many guidances on electronic health and fitness systems (DHT) to be utilised in drug scientific trials by the conclusion of the 12 months. Even though it has issued guidances on digital health and fitness merchandise normally, there is nevertheless concern about regardless of whether this kind of merchandise are correct and trusted ample to gather information for the drug progress approach.
 
As section of FDA’s commitment under the Prescription Drug Person Rate Act (PDUFA VII), the company printed a framework on 23 March on how it ideas to tackle long-standing thoughts on the use of DHTs in drug scientific trials.
 
The agency has proven a steering committee with employees from its drug, system, and biologics overview centers as well as its Electronic Health and fitness Middle of Excellence and its Oncology Centre of Excellence to be certain constant guidelines across the agency, in accordance to the framework.
 
Dependable plan throughout the review centers when it will come to DHTs has been a important concern, according to Bradley Merrill Thompson, lawyer at Epstein Becker Environmentally friendly and general counsel for the Medical Conclusion Guidance (CDS) Coalition.
 
One  chronic stress for the professional medical goods improvement sector is seemingly inconsistent electronic unit policies amongst Food and drug administration centers, Thompson said.
 
“[The Center for Devices and Radiological Health (CDRH)] generally develops steering on digital topics with out [the Center for Drugs Evaluation and Research (CDER)], and then when all those advice paperwork are relied upon in link with a electronic wellness technological know-how made use of with drugs, CDER wishes to just take a refreshing seem at the plan and may perhaps or might not observe CDRH’s guide,” reported Thompson. “That produces excellent uncertainty for market.”
 
In the framework, Food and drug administration lays out several ways it strategies to choose to deal with the situation.
 
“Review divisions and facilities ought to have regular strategies to the assessment and analysis of submissions that have DHT-relevant knowledge,” Fda explained. “The DHT Steering Committee will aid facilitate consistent approaches to the critique and analysis of these kinds of submissions.”
 
Thompson states he hopes the company follows by on its term to develop steady policies.
 
“It may be that they just program to accomplish regularity across CDER review divisions, which would pass up the level,” he mentioned. “I truly hope they seek out consistency across testimonials done by CDRH and CDER.”
 
Thompson also notes that the Food and drug administration tends to involve product high-quality techniques on DHTs employed in scientific trials when it is not warranted. A wide assortment of these kinds of technologies are used in trials, from administrative analyze help software to distant client care and monitoring solutions.
 
“FDA looks to consider the placement that these merchandise satisfy the definition of a healthcare product, even if the functions are reduced danger and not meant for eventual commercialization them selves,” said Thompson.
He argues that even though DHTs are protected in the context of medical reports and meet up with excellent medical follow requirements, numerous of them would not comply with the agency’s regulatory prerequisites, these types of as people for style controls. Suitable now, it’s unclear how Fda plans to apply structure controls to products that might be applied in scientific trials.
 
“On the entire, I am happy they laid out this framework,” Thompson explained. “That’s extremely useful, and it permits sector to make tips.” 
 
“I undoubtedly respect their strategy to give better emphasis to this space and go after much more education,” he extra. “Much of the framework is welcomed. I am just fearful about regardless of whether this is going to handle our most important problems.”
 
In addition to the steering committee, Fda states it will carry on to increase complex expertise internally and deliver coaching in the area of DHTs – together with employing much more individuals with the suitable know-how. The agency states it will also examine statistical criteria when DHT facts is applied to evaluate client information and the IT capabilities necessary to use DHTs.
 
Externally, Food and drug administration strategies to convene the very first of 5 public meetings by the stop of the second quarter of FY2023, bringing  stakeholders collectively to go over the use of DHTs in scientific trials. The meetings will examine subject areas these types of as what to prioritize when producing DHTs, and what methods to get when verifying and validating DHTs.
 
Fda has now put out a couple of draft guidances linked to DHTs including a December 2021 assistance on working with DHTs to remotely obtain facts from clinical trials and an up-to-date March 2023 assistance on use of digital devices, records, and signatures in scientific trials. The company suggests it options to publish two more draft guidances by the conclude of the 12 months like a single on decentralized scientific trials and one more on prescription drug use-related application. (Linked: Fda revises direction on digital techniques and signatures in medical trials, Regulatory Focus, 15 March 2023) (Connected: Stakeholders want much more clarity about equipment employed for distant medical scientific tests, Regulatory Focus, 24 March 2022)
 
DHT Framework

Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials

Evidence from ClinicalTrials.gov on the growth of Digital Health Technologies in neurology trials

The burden of neurological disorders is growing in the US and abroad, with neurological conditions representing the most frequent cause of disability worldwide1. The resulting consequences are considerable individual suffering and substantial societal healthcare costs2,3. R&D investments are needed to identify new therapies, but clinical research faces challenges including high costs, administrative hurdles, and challenging patient recruitment4,5,6. Furthermore, clinical trials and their associated follow-up visits burden patients and their relatives7, especially for those with highly disabling neurological diseases.

Against this backdrop, the use of digital tools, such as connected sensors, promises to make research more patient-centered and move clinical trials beyond single “snapshots” of disease status toward more continuous measurement of chronic disorders8. Connected digital products9 or Digital Health Technologies (DHTs)10,11 are software-containing, patient-focused, portable, and connected sensors of health-related measurements, which describe different products, including many wearables. DHT examples from current FDA guidance include spirometers with smart connectivity, consumer activity trackers, and mobile applications for patients to report outcomes11. Such connected sensors may improve both the quantity and quality of data collection during clinical trials and enable patient recruitment in a less burdensome and more patient-empowering remote setting9.

In neurological diseases such as Parkinson’s disease (PD), use of validated, reliable, and sensitive tools has already been shown to provide better data on the “real-life distribution of disease severity, as it fluctuates longitudinally” in early-stage patients12,13. DHTs can therefore facilitate new study designs12, improve the efficiency of clinical trials14,15,16, and contribute to tackling many of the challenges neurological research faces. As more researchers adopt such technologies, understanding the use and development of DHTs in neurological clinical trials will be valuable for investigators, practicing clinicians, and those designing patient care pathways. As such, this study documents trends in the use of DHTs in neurology research and highlights opportunities for both R&D activities and care delivery going forward.

We assessed studies registered on ClinicalTrials.gov for four exemplary chronic neurological disorders. Building on methods from Marra et al. (2020)9, we identified trial-indication pairs for clinical studies in epilepsy, the neuroinflammatory disease multiple sclerosis (MS), and the two neurodegenerative diseases, PD and Alzheimer’s disease (AD). We present quantitative and qualitative (categorical) analyses of the trials that used connected sensors to describe technology adoption in neurology research and outline underlying trends over the years 2010-2021, inclusive.

Of the 6763 trial-indication pairs for epilepsy, MS, AD, and PD considered, 503 trial-indication pairs were identified as using DHTs by our search algorithm. After manual verification, 441 trial-indication pairs, associated with 430 unique clinical trials, were determined to be relevant and included in the analysis sample (Supplementary Fig. 1). Analysis sample trial counts varied significantly across indications: most frequent were studies in PD (198, 44.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), followed by MS (119, 27.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), AD (87, 19.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and epilepsy (37, 8.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}).

We document growth in the use of DHTs in neurological clinical trials, with a compound annual growth rate of ~39{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} from 2010 – 2020, consistent with trends in DHT growth that have been documented in registered clinical studies more broadly9. Most analyzed trials were interventional, with DHT trials based on registries having started only in recent years and typically incorporating some kind of digital activity or speech tracking (Fig. 1).

Fig. 1: Development of clinical trials for chronic neurological diseases by year of initiation, trial type and indication.
figure 1

a Number of analyzed studies using Digital Health Technologies (DHTs) per year, stratified by the type of the respective trial. Line depicts the percentage of DHT trials out of all trials for the analyzed indications starting in the respective year. b Number of analyzed studies using DHTs per year, stratified by the indications epilepsy (Epi.), Alzheimer’s disease (AD), multiple sclerosis (MS), and Parkinson’s disease (PD). * Data for the year 2021 may be incomplete due to late registrations on ClinicalTrials.gov.

The relative frequency of DHT use in trials for the focal conditions increased from 0.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of trials in 2010 to 11.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} in 2020. PD trials showed early uptake of DHTs and the highest use rate over the full period of the study (8.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} on average). AD, MS, and epilepsy trials showed a delayed upward trend, with respective use rates of 7.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}, 5.8{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}, and 3.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} overall (Supplementary Table 1).

Among all DHT trials, 16.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} included an industry sponsor or collaborator – slightly less frequently than the 19{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} previously documented across all medical disciplines9 – with industry partnerships more commonly observed in trials for epilepsy (37.8{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and AD (23.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) (see Supplementary Fig. 2).

With respect to studies’ categorical (qualitative) features, most trials tracked patient symptoms (91.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), with exceptions focusing on vital signs of caregivers or other disease-related outcomes such as medication adherence. The majority of trials measured motor functions (68.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), with many including exercise elements (34.7{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), sometimes through the use of gaming consoles (7.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}). Sleep (15.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), cognition (10.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and speech (4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) tracking were less common as were gamification (19.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), caregiver support (6.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), and medication adherence (4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) elements (Table 1). A large share of studies used some form of mobile application (35.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and the most commonly referenced DHTs were wearables (129, 29.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), smartphones (76, 17.2{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), actigraphs (48, 10.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) and mobile applications (42, 9.5{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}) (see Supplementary Table 2).

Table 1 Qualitative (categorical) features of trials by indication.

PD and MS trials often focused on motor symptoms and physical exercise, with a high share of gamification elements in MS trials. Other observed characteristics included numerous caregiver support and speech recognition tools in AD trials, frequent sleep tracking in AD and epilepsy trials, cognition tracking in AD and MS trials, and a recurrent tracking of medication adherence in epilepsy trials (Table 1).

Generally, a trend toward more complex and more extensive studies was observed, as represented by a gradual change in categorical trial features over time (Fig. 2). Whereas the use of motor function and exercise tracking were already observed in 2010, speech and cognition tracking were not observed until the mid-2010s (Fig. 2). Speech and cognition tracking both grew over time and were present in 8.1{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} and 14.0{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} of analyzed DHTs using trials in 2021, respectively (Supplementary Table 1). Conversely, the relative use of gamification elements decreased slightly in more recent years (Supplementary Table 1).

Fig. 2: Use of selected Digital Health Technology tracking modalities in trials registered on ClinicalTrials.gov for chronic neurological diseases by year of trial initiation.
figure 2

Number of ClinicalTrials.gov registered trials of four different neurological indications using DHTs for different tracking modalities by trial initiation year (green bar plots). Additionally, rate of these studies compared to all trials for the same indications registered on ClinicalTrials.gov for the respective year is shown (orange line). Trials for the indications epilepsy, Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease were included. a Absolute number and share of all trials for motor function tracking. b Absolute number and share of all trials for sleep tracking. c Absolute number and share of all trials for cognition tracking. d Absolute number and share of all trials for speech tracking. * Data for the year 2021 may be incomplete due to late registrations on clinicaltrials.gov.

Most registered trial-indication pairs were identified in North America or Europe, with a large share of trials having principal investigators in the US (209, 47.4{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), followed by Italy and France (both 28 or 6.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} each), the UK (19, 4.3{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Belgium (17, 3.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Switzerland (16, 3.6{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Israel (14, 3.2{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f}), Canada, Turkey, and Germany (all 13 or 2.9{08cd930984ace14b54ef017cfb82c397b10f0f7d5e03e6413ad93bb8e636217f} each). In total, trials from 33 countries and all inhabited continents were included in the analysis sample. Some regions showed a local/regional concentration of DHT studies, often related to a specific indication. An interactive map displaying the locations of sample trials are publicly accessible at https://www.reine-nervensache.de/eigene-forschungsergebnisse/digital-health-technologies-in-neurology-trials.

Qualitatively, included studies displayed heterogeneity in their aims. Whereas some clinical trials aimed to validate products or novel biomarkers, others already applied them as endpoints in studies of other interventions.

While some have highlighted insufficient prospective clinical research applying DHTs and mobile health17, the use of DHTs in neurology trials has not previously been characterized in detail. We analyzed disease-specific DHT adoption in trials registered on ClinicalTrials.gov to provide insights specific to four chronic neurologic diseases.

The analysis confirmed a clear trend in DHT adoption, with some disease-specific heterogeneity. The earlier application of such tools in disorders with primarily motoric symptoms, such as PD or MS, is likely due to the early availability of wearable sensors to track motor functions and might contribute to the higher number of trials observed for these two indications. However, as novel sensors and sophisticated technical setups became available in more recent years, multimodal clinical trials tackling diverse research questions with DHTs began to emerge. This development is evident in the subset of AD trials, where recent growth in the share of trials using DHTs is consistent with increasing readiness of novel digital measures that integrate speech and cognition tracking18,19. In parallel, the repertoire of DHTs used in early-adopting subfields has also expanded, for example through potential PD monitoring technologies that now include passive tremor monitoring via wearables12,13, smartphone-based motor and vocal symptom assessments20,21, gait analysis via smart insoles22, and sensors for swallowing23.

Interestingly, pharmaceutical companies tested self-developed DHTs in some trials24,25,26, indicating a possibility for broader prospective adoption by other stakeholders. Differences in the share of industry-sponsored trials across neurologic diseases could indicate differences in experience with digital measures across indications or difference in research funding for different diseases (either within firms themselves and/or from investments by research foundations or public funders). Any of these factors could shape biopharmaceutical and medical device firms’ investments in their use in clinical trials. Regions with a higher density of clinical trials using DHTs differ in their indication-specificity, suggesting different backgrounds and foci of research teams: high-density areas with multiple indications were more frequent in the US and could indicate technology-driven research, whereas regional clusters focusing on research in a single indication appeared more common in other countries.

Some digital measures assessed in the analysis sample integrate information previously unavailable to clinicians and researchers, such as details of smartphone usage27 or characteristics of patient-caregiver-interactions28,29, in one case deploying real-time monitoring of mood and stress via a smart-home approach29. Monitoring cognitive and motor skills with ‘byproduct data’ such as metadata on smartphone keystroke dynamics, for example, in epilepsy27 or MS30, could allow remote monitoring to be passively and therefore more seamlessly integrated into patients’ daily lives and eventually, into clinical routines. Further examples of the use of previously inaccessible data for novel phenotyping include approaches such as longitudinal repetitive cognitive testing18,31, speech characterization32, or swallowing monitoring23. Especially in more complex recent studies, digital biomarkers or measures were observed in conjunction with biological and radiological biomarkers22,33, promising a more detailed overview of patients’ health status than ever before. Furthermore, the small but growing trend of monitoring and supporting caregivers or relatives via DHTs28,29 could preview new forms of promising assistance for these essential but often neglected alleviators of the burdens of chronic diseases. A personalized prevention of secondary burn-out or depression among caregivers could be supported by DHTs that objectively track interactions with patients and monitor caregivers’ vital signs and stress28,29.

The observed heterogenous use pattern of DHTs in the analysis sample highlights different use cases for validating DHTs, gathering data with DHTs, or using DHTs as interventions; understanding this heterogeneity should be a focus of future research. Examples of trials categorized by the use cases according to Marra et al.9 can be found in Supplementary Table 3. Generally, there appears to be a large variety of new therapeutic and monitoring solutions under study, although solutions often remain fragmented, stand-alone approaches, making it difficult to bring user-friendly, holistic approaches into practice at scale.

The growing share of disease-specific trials applying DHTs show that neurological research is already adapting and increasingly integrating remote digital measurements into its research agenda. In addition to growing adoption of established digital measures, such as motor function, novel approaches, such as speech and cognition tracking are being deployed more often.

Recent regulatory trends further support this development, as seen in the first qualification of a digital endpoint by the EMA in Duchenne muscular dystrophy34, a neuromuscular disorder, and published guidance for applying DHTs by the FDA11. Nevertheless, there remains ample opportunity to extend the use of DHTs in clinical trials and support their transition into routine clinical care. Different technologies promise improved patient healthcare access and new setups for decentralized clinical trials, thereby enabling previously unimaginable measures for gathering real-world evidence. Further research is needed to clarify what is required for broader adoption in practice, thus enabling the translation of verified, analytically validated, and clinically validated tools35 into improved patient care.

Methods

We identified DHTs in trials registered on ClinicalTrials.gov following Marra et al. (2020)9 and using an updated and curated version of the searched product list (see Supplementary Note 1 and GitHub repository in the Data Availability Statement). Additionally, trials were filtered for the conditions epilepsy, MS, AD, or PD, resulting in a dataset built around unique trial-indication pairs (only 10 trials had multiple indications). The analysis sample was restricted to trials launched from 2010–2021 (inclusive) that had at least begun recruitment. Data were retrieved on February 28th, 2022. The resulting set of records was analyzed for the use of DHTs and trials that referenced such products were included in the analysis and mapped to a list of relevant categories defined for this purpose. This list included non-mutually-exclusive features such as different tracking characteristics as listed in Table 1 and Supplementary Table 1 (mapping was carried out by L.M. and P.G.). For comparison, other contemporaneous trials for the same indications were pulled from ClinicalTrials.gov. All analyses were run using Python 3.8 (Python Software Foundation, Delaware, USA). An interactive map of the principal trial locations was generated using plotly version 5.4.036 after geocoding addresses with geopy version 2.2.037. The co-author team included a patient with one of the focal disorders.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.